8-K: Structure Therapeutics Announces Positive Topline Results for Oral GLP-1 Agonist GSBR-1290 in Obesity Studies

Structure Therapeutics reports positive topline data from Phase 2a obesity and capsule to tablet PK studies for its oral GLP-1 receptor agonist, GSBR-1290, showing significant weight loss and favorable safety.

Summary

• Structure Therapeutics announced positive topline results from two studies of its oral GLP-1 receptor agonist, GSBR-1290.
• The Phase 2a obesity study showed a statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks.
• In the Phase 2a study, 67% of participants on GSBR-1290 achieved at least 6% weight loss, and 33% achieved at least 10% weight loss, compared to 0% in the placebo group.
• A capsule to tablet PK study demonstrated a placebo-adjusted mean weight loss of up to 6.9% at 12 weeks with the tablet formulation.
• The tablet formulation showed comparable exposure to the capsule formulation, supporting a once-daily dose profile.
• GSBR-1290 demonstrated generally favorable safety and tolerability, with gastrointestinal-related adverse events being the most common.
• Adverse event-related study discontinuations ranged from 5% in the Phase 2a obesity study to 11% in the capsule to tablet PK study.
• There were no cases of drug-induced liver injury or persistent liver enzyme elevations reported in either study.
• The company plans to submit an IND to the FDA in the third quarter of 2024 to support trials in chronic weight management.
• A Phase 2b obesity study of GSBR-1290 is expected to begin in the fourth quarter of 2024, with approximately 300 participants.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a clear path forward for further development. The company's management is optimistic, and the data suggests a strong potential for the drug. However, there are still risks associated with clinical trials and regulatory approvals.

Positives

• GSBR-1290 demonstrated clinically meaningful and statistically significant weight loss in both studies.
• The tablet formulation of GSBR-1290 is comparable to the capsule formulation and supports once-daily dosing.
• The safety and tolerability profile of GSBR-1290 is favorable, with low rates of study discontinuations.
• The company is progressing towards a Phase 2b study in obesity, indicating continued development of the drug.
• The manufacturing process for GSBR-1290 is expected to be scalable to meet global demand.
• The data suggests GSBR-1290 has the potential to be a best-in-class oral GLP-1RA.

Negatives

• Gastrointestinal-related adverse events, such as nausea and vomiting, were the most common side effects.
• AE-related study discontinuations ranged from 5% to 11%, indicating some tolerability issues.
• The results are based on a 12-week study, and long-term efficacy and safety data are still needed.

Risks

• The topline results are based on a preliminary analysis and may change after a more comprehensive review.
• The results from earlier clinical trials may not be predictive of future results.
• There are potential delays in the IND submission or commencement, enrollment, and completion of planned Phase 2 trials.
• The company needs to receive allowance from the FDA before initiating the planned Phase 2b trial.
• Competitive products or approaches could limit the commercial value of the company's product candidates.
• The company's ability to fund development activities and achieve development goals is subject to risks.
• Global pandemics, inflation, supply chain issues, and rising interest rates could impact the company's business.

Future Outlook

The company plans to submit an IND to the FDA in the third quarter of 2024 and initiate a Phase 2b obesity study in the fourth quarter of 2024. They are also exploring higher doses in future studies and developing next-generation combination GLP-1R candidates.

Management Comments

• Raymond Stevens, Ph.D., Founder and CEO of Structure, stated that the topline results demonstrate the substantial weight loss effect of GSBR-1290 and its potential to become a best-in-class oral small molecule GLP-1RA.
• Dr. Stevens also mentioned that the company is pleased with the performance of the new tablet formulation and the start low and go-slow titration strategy.
• Ania Jastreboff, M.D., Ph.D., noted the need for oral treatments for obesity and that the data with GSBR-1290 is encouraging for its development as a potential future therapeutic.

Industry Context

The announcement is significant as it highlights the potential of oral small molecule GLP-1 receptor agonists in the treatment of obesity, which is a growing global health concern. The results position Structure Therapeutics as a potential competitor in the GLP-1 market, which is currently dominated by injectable peptide-based therapies. The company is also developing next-generation combination GLP-1R candidates together with GIP, amylin, glucagon and apelin oral small molecules.

Comparison to Industry Standards

• The 6.2% to 6.9% placebo-adjusted weight loss observed with GSBR-1290 at 12 weeks is competitive with other oral GLP-1R agonists in development.
• Orforglipron, another oral GLP-1RA, showed approximately 6.5% weight loss at 12 weeks in a 36-week study, while Danuglipron showed 6.6% weight loss at 12 weeks.
• Oral Semaglutide, a peptide-based GLP-1RA, showed approximately 3.7% weight loss at 12 weeks in a 68-week study.
• GSBR-1290's results are particularly notable given its small molecule nature, which offers potential advantages in terms of manufacturing scalability and cost compared to peptide-based therapies.
• The safety profile of GSBR-1290 appears to be generally favorable, with low rates of study discontinuations, although gastrointestinal side effects are common, as expected for this class of drugs.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical trial results.
• Employees may be motivated by the progress of the company's lead drug candidate.
• Patients with obesity may benefit from the development of a new oral treatment option.
• Suppliers and collaborators may see increased business opportunities.
• Creditors may view the company as a more attractive investment.

Next Steps

• The company plans to submit an IND to the FDA in the third quarter of 2024.
• The company plans to initiate a Phase 2b obesity study in the fourth quarter of 2024.
• The company will continue to develop next-generation combination GLP-1R candidates.

Key Dates

Keywords

GSBR-1290, GLP-1 receptor agonist, obesity, weight loss, clinical trial, Phase 2a, Phase 2b, oral small molecule, pharmacokinetics, safety, tolerability, tablet formulation